Uncategorized

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Merck announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Read More »

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development Read More »

Scroll to Top